Fosfomycin tromethamine
Alternative Names: Fosfomycin trometamol; FZ 588; Monofoscin; Monuril; Urizone; Z 1282Latest Information Update: 13 Apr 2022
At a glance
- Originator Zambon Group SpA
- Developer AbbVie; Adcock Ingram Pharmaceuticals; Inpharzam Ricerche S.A.; Mayne Pharma Group; Orion; Rontag; Roux Ocefa; Zambon Company SpA
- Class Antibacterials; Epoxy compounds; Organophosphorus compounds; Phosphonic acids; Phosphoric acid esters; Small molecules
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Urinary tract infections
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 25 Sep 2017 Launched for Urinary tract infections in Turkey, Mexico, Indonesia, Taiwan, Philippines, Malaysia, Lebanon, Hong Kong, China, Thailand, Israel, Peru, Tunisia, Slovenia, Russia (PO)
- 15 Sep 2017 Fosfomycin tromethamine licensed to Mayne Pharma Group in Australia